Reuters logo
BRIEF-Prometic says FDA grants orphan drug designation to its PBI-4050 drug
March 3, 2017 / 11:36 AM / in 9 months

BRIEF-Prometic says FDA grants orphan drug designation to its PBI-4050 drug

March 3 (Reuters) - Prometic Life Sciences Inc

* US FDA grants orphan drug designation to Prometic’s PBI-4050 drug for the treatment of alström syndrome

* Prometic Life Sciences - currently investigating effects of PBI-4050 on multiple organs in as patients in ongoing, open label, phase 2, clinical study in UK Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below